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E D I T O R I A L S
Liver enzymes and all‐cause mortality: Open issues
Elevated	serum	levels	of	aspartate	aminotransferase	(AST),	gamma‐
glutamyltransferase	 (GGT)	 and	 alanine	 aminotransferase	 (ALT)	 are	
markers	of	 liver	 injury	and	have	been	consistently	 related	 to	mor‐
tality	from	liver	disease.	A	possible	role	of	liver	enzymes	as	markers	
of	all‐cause	mortality	and	mortality	from	non	liver	diseases,	includ‐
ing	mainly	cardiovascular	diseases	(CVD),	cerebrovascular	diseases,	
cancer	and	diabetes,	is	yet	to	be	clarified	and	quantified.	In	addition,	
although	the	issue	has	been	addressed	among	individuals	negative	
for	viral	hepatitis	B	(HBV)	and/or	C	(HCV)	serum	markers,1,2	limited	
data	are	available	among	individuals	with	markers	of	hepatitis	virus	
infection.	An	additional	relevant	issue	is	the	possible	interaction	be‐
tween	diabetes,	 vascular	disease,	 cancer	 and	other	 chronic	 condi‐
tions	with	liver	disease	(as	defined	by	elevated	AST,	GGT	and	ALT)	
on	mortality.	To	address	this	issue,	Yuwaki	et	al	present	data	on	the	
relation	between	levels	of	liver	enzymes	and	all‐cause	and	non	liver	
disease	mortality	according	to	HBV/HCV	status	using	data	from	the	
Japan	Public	Health	Center‐based	Prospective	Study.3
That	 large,	 well‐recognized	 Japanese	 study	 indicated	 that	 ele‐
vated	levels	of	AST,	GGT,	but	less	consistently	ALT,	were	associated	to	
excess	total	mortality	(which	includes	a	small	proportion	of	liver	dis‐
eases)	and,	more	importantly,	non	liver	disease	mortality,	among	HBV	
and	HCV	negative	subjects.	The	findings	on	total	mortality	for	AST	
and	GGT	were	consistent	 in	men	and	women,	and	the	associations	
were	 significant	 after	 allowance	 for	 a	 large	number	of	 risk	 factors,	
including	tobacco,	alcohol,	body	mass	index	(BMI),	physical	activity,	
energy	intake,	hypertension,	hyperglycaemia	and	dyslipidaemia.
The	 associations	 between	 liver	 enzymes	 and	 non	 liver	 disease	
mortality	were	however	inconsistent	in	subjects	positive	for	hepatitis	
virus	infection,	i.e.	subjects	with	HBV	surface	antigen	and/or	anti‐HCV	
antibody	 serum	 markers.	 In	 those	 subjects,	 liver	 disease	 mortality	
accounted	 for	 over	 50%	of	 total	mortality,	 in	 both	 sexes	 combined	
among	subjects	with	elevated	levels	of	serum	liver	enzymes,	and	num‐
ber	of	deaths	were	limited	across	strata	for	non	liver	disease	mortality.	
Thus,	an	overall	analysis	of	non	liver	disease	mortality	in	both	sexes	
combined	would	have	been	informative.	For	instance,	the	hazard	ra‐
tios	(HR)	according	to	GGT	were	above	unity	for	both	50‐100	IU/l	and	
>100	IU/l	vs	the	reference	category	<50	IU/l,	but	there	were	only	32	
deaths	from	non	liver	disease	in	men	and	six	in	women	in	the	interme‐
diate	level	and	18	in	men	and	four	in	women	in	the	highest	level	stra‐
tum.	Consequently,	both	sex‐specific	trends	were	only	of	borderline	
significance.	In	any	case,	it	is	reasonable	to	assume	that	high	levels	of	
liver	enzymes,	as	markers	of	liver	disease,	are	associated	to	non	liver	
disease	mortality	in	subjects	positive	for	hepatitis	viruses	markers,	too.
Among	hepatitis	virus	negative	subjects,	non	liver	disease	mor‐
tality	accounted	for	about	95%	of	deaths	in	both	sexes	among	sub‐
jects	with	elevated	levels	of	AST,	ALT	and	GGT.	Therefore,	the	HR	
for	non	 liver	disease	mortality	were	 less	strong	than	those	for	all‐
cause	mortality,	but	essentially	reflected	the	patterns	observed	for	
total	mortality	for	both	levels	of	intermediate	and	high	liver	enzymes	
(AST,	ALT	and	GGT).
Thus,	 the	 excess	non	 liver	 disease	mortality	 among	HBV/HCV	
negative	 subjects	with	 high	 liver	 enzymes	 levels	 can	 be	 due	 to	at	
least	four	factors,	i.e.	(a)	some	misclassification	of	causes	of	death,	
though	this	is	likely	relatively	minor	in	Japan;	(b)	the	presence	of	liver	
disease,	which	may	complicate	other	conditions	and	be	a	concom‐
itant	 cause	 of	 death;	 (c)	 the	 presence	 of	 common	 risk	 factors	 for	
non	viral	liver	diseases	and	other	major	causes	of	death,	i.e.	vascular	
diseases	and	cancer;	and	(d)	the	release	by	other	organs	of	liver	en‐
zymes	even	in	the	absence	of	liver	(hepatocellular)	injury.4
The	first	two	possible	factors	have	to	be	mentioned	and	may	well	
be	important,	but	there	is	little	possibility	and	scope	for	their	discus‐
sion	on	available	data.
The	presence	of	common	risk	factors	has	however	to	be	further	
discussed.	In	fact,	besides	hepatitis	and	alcohol,	the	main	cause	of	liver	
disease	is	non	alcoholic	fatty	liver	disease	(NAFLD),	which	is	essentially	
due	to	hypertension,	dyslipidaemia,	overweight	and	type	2	diabetes,	
i.e.	the	key	components	of	the	metabolic	syndrome	(MetS).5‐7	These	
conditions	are	established	risk	factors	for	CVD,	and	CVD	represents	
one	of	the	major	causes	of	death	among	patients	with	NAFLD.8	There	
is	also	some	evidence	that	MetS9	and	NAFLD	are	associated	with	an	
increased	risk	of	colorectal	cancer10	and	possibly	other	neoplasms.11
In	addition,	specific	factors	of	MetS	(which	is	the	key	determinant	of	
NAFLD),	notably	obesity	and	diabetes,	have	been	associated	with	the	
risk	of	some	common	cancers.	According	to	the	International	Agency	
for	Research	on	Cancer	(IARC),	excess	body	weight	increases	the	risk	of	
at	least	13	neoplasms,	including,	besides	liver	cancer,12	endometrial,	oe‐
sophageal,	renal	and	pancreatic	adenocarcinomas,	gastric	cardia	cancer,	
colorectal,	 post‐menopausal	 breast,	 ovarian,	 gallbladder	 and	 thyroid	
cancers.13	 Type	 2	 diabetes	 is	 a	 risk	 factor	 for	 liver	 cancer	 and	 col‐
orectal,	pancreatic,	endometrial	and	perhaps	post‐menopausal	breast	
cancer.14,15	There	 is	 also	 some	 indication	 for	an	association	between	
dyslipidaemia	and	 liver,	 as	well	 as	breast,	 lung,	prostate	and	colorec‐
tal	cancers.16	In	addition,	MetS	has	been	related	to	the	development	of	
hepatocellular	carcinoma	(HCC)	as	well	as	colorectal,	pancreatic,	endo‐
metrial,	post‐menopausal	breast	and	ovarian	cancer11	and	also	to	over‐
all	cancer	death.17	Excessive	alcohol	consumption	is	a	further	common	
risk	factor	for	cirrhosis,	and	hence	HCC,	and	several	other	major	causes	
of	disease	and	death,18	 including	various	types	of	cancer,	particularly	
those	of	the	upper	aerodigestive	tract,	colorectum	and	breast.19
See	Article	on	Page	1566
1390  |     EDITORIAL
Thus,	 given	 the	presence	of	 common	 risk	 factors	 for	non	viral	
liver	diseases	and	other	leading	causes	of	death,	it	is	plausible	that	
HBV	 and	HCV	 negative	 subjects	with	 liver	 injuries	 (elevated	 liver	
enzymes)	have	also	an	excess	of	mortality	from	non	liver	diseases.
The	data	on	non	liver	disease	mortality	among	HBV/HCV	posi‐
tive	subjects	were	limited	in	the	Japan	Public	Health	Center‐based	
Prospective	Study.	However,	particularly	in	women,	they	were	com‐
patible	 to	 some	excess	 deaths	 among	 subjects	with	 elevated	 liver	
enzymes.	This	 is	reasonable,	 since	AST,	ALT	and	GGT	are	markers	
of	 liver	 disease,	which	may	 interact	with	 other	 chronic	 conditions	
(CVD,	cancer,	etc)	to	cause	death.	HCV	and	perhaps	HBV	have	also	
been	related	to	excess	lymphoma	risk,20	whose	mortality	may	be	in‐
creased	by	liver	conditions.
Thus,	the	data	of	the	Japan	Public	Health	Center‐based	Prospective	
Study	indicate	that	high	levels	of	AST,	ALT	and	GGT	are	related	not	
only	to	total	but	also	to	non	liver	disease	mortality	in	hepatitis	marker	
negative	subjects,	though	this	essentially	reflects	the	pattern	of	total	
mortality,	owing	to	the	small	proportion	of	deaths	from	liver	diseases	
in	HBV/HCV	markers	negative	subjects.	They	are	also	suggestive	of	
a	 role	of	 these	markers	 as	 indicators	of	 non	 liver	disease	mortality	
among	hepatitis	markers	positive	 subjects	 in	both	 sexes	 combined,	
although	the	numbers	are	small	for	definite	conclusions.
On	a	mechanistic	level,	hypertension,	dyslipidaemia,	overweight	
and	diabetes	 (i.e.	 the	key	components	of	the	MetS)	are	associated	
to	non	HBV/HCV‐related	 liver	diseases,	and	are	major	 risk	 factors	
for	vascular	diseases,	selected	cancers	and	hence	(non	liver	disease)	
mortality.	This	may	well	explain	why	elevated	serum	levels	of	 liver	
enzymes	are	indicators	of	non	liver	disease	mortality,	too.
Open	issues	include	the	mechanistic	interpretation	of	the	asso‐
ciations	between	liver	enzymes	and	non	liver	disease	mortality,	i.e.	
whether	elevated	liver	enzymes	are	simply	markers	of	NAFLD	and	
hence	the	MetS.	An	additional	open	issue	is	whether	liver	enzymes	
are	 related	 to	 excess	 non	 liver	 disease	mortality	 in	 hepatitis	 virus	
positive	subjects,	too.
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